1921
Volume 93, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

The protozoan triggers an inflammatory process in mammalian heart causing events such as fibrosis, changes in the architecture and functionality in this organ. Enalapril, an angiotensin II-converting enzyme inhibitor, is a drug prescribed to ameliorate this heart dysfunction, and appears to exert a potential role in immune system regulation. Our aim was to evaluate the chronic cardiac inflammatory parameters after therapeutic treatment with enalapril and benznidazole in C57BL/6 mice infected with the VL-10 strain of . After infection, animals were treated with oral doses of enalapril (25 mg/kg), benznidazole (100 mg/kg), or both during 30 days. Morphometric parameters and levels of chemokines (CCL2, CCL5), IL-10, creatine kinases (CKs), and C-reactive protein were evaluated in the heart and serum at the 120th day of infection. Enalapril alone or in combination with benznidazole did not change the number of circulating parasites, but reduced cardiac leukocyte recruitment and total collagen in the cardiac tissue. Interestingly, the combination therapy (enalapril/benznidazole) also reduced the levels of chemokines, CK and CK-MB, and C-reactive proteins in chronic phase. In conclusion, during the chronic experimental infection, the combination therapy using enalapril plus benznidazole potentiated their immunomodulatory effects, resulting in a low production of biomarkers of cardiac lesions.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.15-0237
2015-11-04
2017-09-23
Loading full text...

Full text loading...

/deliver/fulltext/14761645/93/5/976.html?itemId=/content/journals/10.4269/ajtmh.15-0237&mimeType=html&fmt=ahah

References

  1. Toledo MJ, de Lana M, Carneiro CM, Bahia MT, Machado-Coelho GL, Veloso VM, Barnabé C, Tibayrenc M, Tafuri WL, , 2002. Impact of Trypanosoma cruzi clonal evolution on its biological properties in mice. Exp Parasitol 100: 161172.[Crossref]
  2. Rossi MA, , 1991. The pattern of myocardial fibrosis in chronic Chagas' heart disease. Int J Cardiol 30: 335340.[Crossref]
  3. Prata A, , 2001. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 1: 92100.[Crossref]
  4. Tassi EM, Continentino MA, Nascimento EM, Pereira B de B, Pedrosa RC, , 2014. Relationship between fibrosis and ventricular arrhythmias in Chagas heart disease without ventricular dysfunction. Arq Bras Cardiol 102: 456464.
  5. Coura JR, Borges-Pereira J, , 2011. Chronic phase of Chagas disease: why should it be treated? A comprehensive review. Mem Inst Oswaldo Cruz 106: 641645.[Crossref]
  6. Rassi A, Jr Rassi A, Marin-Neto JA, , 2010. Chagas disease. Lancet 17: 13881402.[Crossref]
  7. Botoni FA, Ribeiro AL, Marinho CC, Lima MM, Nunes M do C, Rocha MO, , 2013. Treatment of Chagas cardiomyopathy. BioMed Res Int 2013: 849504.[Crossref]
  8. Leon JS, Wang K, Engman DM, , 2003. Captopril ameliorates myocarditis in acute experimental Chagas disease. Circulation 107: 22642269.[Crossref]
  9. Paula-Costa G, Silva RR, Pedrosa MC, Pinho V, de Lima WG, Teixeira MM, Bahia MT, Talvani A, , 2010. Enalapril prevents cardiac immune-mediated damage and exerts anti-Trypanosoma cruzi activity during acute phase of experimental Chagas disease. Parasite Immunol 32: 202208.[Crossref]
  10. Botoni FA, Poole-Wilson PA, Ribeiro AL, Okonko DO, Oliveira BM, Pinto AS, Teixeira MM, Teixeira AL, Jr Reis AM, Dantas JB, Ferreira CS, Tavares WC, Jr Rocha MO, , 2007. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Am Heart J 153: e1e8.[Crossref]
  11. Melo L, Caldas IS, Azevedo MA, Gonçalves KR, Nascimento AFS, Figueiredo VP, Diniz LF, Lima WG, Torres RM, Bahia MT, Talvani A, , 2011. Low doses of simvastatin therapy ameliorate cardiac inflammatory remodeling in Trypanosoma cruzi-infected dogs. Am J Trop Med Hyg 84: 325331.[Crossref]
  12. Silva RR, Shrestha-Bajracharya D, Almeida-Leite CM, Leite R, Bahia MT, Talvani A, , 2012. Short-term therapy with simvastatin reduces inflammatory mediators and heart inflammation during the acute phase of experimental Chagas disease. Mem Inst Oswaldo Cruz 107: 513521.[Crossref]
  13. Ferrario CM, Strawn WB, , 2006. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 98: 121128.[Crossref]
  14. Sciarretta S, Paneni F, Palano F, Chin D, Tocci G, Rubattu S, Volpe M, , 2009. Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. Clin Sci (Lond) 116: 467477.[Crossref]
  15. Yokota T, Tomita H, Mori Y, Kudo T, Hiraga H, Suto N, Higuma T, Abe N, Hanada H, Osanai T, Okumura K, , 2014. Imidapril and enalapril similarly inhibit plasma matrix metalloproteinase activities and attenuate left ventricular remodeling in patients with acute myocardial infarction. J Cardiovasc Pharmacol 63: 528532.[Crossref]
  16. Rompe F, Artuc M, Hallberg A, Alterman M, Stroder K, Thone-Reineke C, Reichenbach A, Scharcherl J, Dahlof B, Bader M, Alenina N, Schwaninger M, Zuberbier T, Funke-Kaiser H, Schmidt C, Schunck WH, Unger T, Steckelings UM, , 2010. Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension 55: 924931.[Crossref]
  17. Brener Z, , 1962. Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi . Rev Inst Med Trop Sao Paulo 4: 389396.
  18. Filardi LS, Brener Z, , 1987. Susceptibility and natural resistance of Trypanosoma cruzi strains to drug used clinically in Chagas disease. Trans R Soc Trop Med Hyg 81: 755759.[Crossref]
  19. Araújo MS, Martins-Filho OA, Pereira ME, Brener Z, , 2000. A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease. J Antimicrob Chemother 45: 819824.[Crossref]
  20. Lannes-Vieira J, Silverio JC, Pereira IR, Vinagre NF, Carvalho CME, Paiva CN, Silva AA, , 2009. Chronic Trypanosoma cruzi-elicited cardiomyopathy: from the discovery to the proposal of rational therapeutic interventions targeting cell adhesion molecules and chemokines receptors—how to make a dream come true. Mem Inst Oswaldo Cruz 104: 226235.[Crossref]
  21. Aliberti JC, Cardoso MA, Martins GA, Gazzinelli RT, Vieira LQ, Silva JS, , 1999. Interleukin-12 mediates resistance to Trypanosoma cruzi in mice and is produced by murine macrophages in response to live trypomastigotes. Infect Immun 64: 19611967.
  22. Talvani A, Ribeiro CS, Aliberti JC, Michailowsky V, Santos PV, Murta SM, Romanha AJ, Almeida IC, Farber J, Lannes-Vieira J, Silva JS, Gazzinelli RT, , 2000. Kinetics of cytokine gene expression in experimental chagasic cardiomyopathy: tissue parasitism and endogenous IFN-gamma as important determinants of chemokine mRNA expression during infection with Trypanosoma cruzi . Microbes Infect 2: 851866.[Crossref]
  23. Gutierrez FR, Mineo TW, Pavanelli WR, Guedes PM, Silva JS, , 2009. The effects of nitric oxide on the immune system during Trypanosoma cruzi infection. Mem Inst Oswaldo Cruz 104 (Suppl 1): 236245.[Crossref]
  24. Brener Z, Gazzinelli RT, , 1997. Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease. Int Arch Allergy Immunol 114: 103110.[Crossref]
  25. Talvani A, Teixeira MM, , 2011. Inflammation and Chagas disease: some mechanisms and relevance. Adv Parasitol 76: 171194.[Crossref]
  26. Rodriguez HO, Guerrero NA, Fortes A, Santi-Rocca J, Gironès N, Fresno M, , 2014. Trypanosoma cruzi strains cause different myocarditis patterns in infected mice. Acta Trop 139: 5766.[Crossref]
  27. Meza SK, Kaneshima EN, Silva S de O, Gabriel M, de Araújo SM, Gomes ML, Monteiro WM, Barbosa M, Toledo MJ, , 2014. Comparative pathogenicity in Swiss mice of Trypanosoma cruzi IV from northern Brazil and Trypanosoma cruzi II from southern Brazil. Exp Parasitol 146: 3442.[Crossref]
  28. Esper L, Talvani A, Pimentel P, Teixeira MM, Machado FS, , 2015. Molecular mechanisms of myocarditis caused by Trypanosoma cruzi . Current Opin Infect Dis 28: 246252.[Crossref]
  29. Coura JR, de Castro SL, , 2002. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 97: 324.[Crossref]
  30. Urbina JA, , 2015. Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives. J Eukaryot Microbiol 62: 149156.[Crossref]
  31. Viotti R, Vigliano C, , 2007. Etiological treatment of chronic Chagas disease: neglected ‘evidence’ by evidence-based medicine. Expert Rev Anti Infect Ther 5: 717726.[Crossref]
  32. Marin-Neto JA, Rassi A, Jr Morillo CA, Avezum A, Connolly SJ, Sosa-Estani S, Rosas F, Yusuf S, BENEFIT Investigators, , 2008. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 156: 3743.[Crossref]
  33. Garcia S, Ramos CO, Senra JF, Vilas-Boas F, Rodrigues MM, Campos-de-Carvalho AC, Ribeiro-Dos-Santos R, Soares MB, , 2005. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob Agents Chemother 49: 15211528.[Crossref]
  34. Olivieri BP, Cotta-De-Almeida V, Araújo-Jorge T, , 2002. Benznidazole treatment following acute Trypanosoma cruzi infection triggers CD8+ T-cell expansion and promotes resistance to reinfection. Antimicrob Agents Chemother 46: 37903796.[Crossref]
  35. Piaggio E, Sance'au J, Revelli S, Bottasso O, Wietzerbin J, Serra E, , 2001. Trypanocidal drug benznidazole impairs lipopolysaccharide induction of macrophage nitric oxide synthase gene transcription through inhibition of NF-κB activation. J Immunol 167: 34223426.[Crossref]
  36. Sathler-Avelar R, Vitelli-Avelar DM, Massara RL, Borges JD, Lana M, Teixeira-Carvalho A, Dias JC, Elói-Santos SM, Martins-Filho OA, , 2006. Benznidazole treatment during early-indeterminate Chagas' disease shifted the cytokine expression by innate and adaptive immunity cells toward a type 1-modulated immune profile. Scand J Immunol 64: 554563.[Crossref]
  37. Cutrullis RA, Moscatelli GF, Moroni S, Volta BJ, Cardoni RL, Altcheh JM, Corral RS, Freilij HL, Petray PB, , 2011. Benzonidazole therapy modulates interferon-γ and M2 muscarinic receptor autoantibody responses in Trypanosoma cruzi-infected children. PLoS One 6: e27133.[Crossref]
  38. Piaggio E, Roggero E, Pitashny M, Wietzerbin J, Bottasso AO, Revelli SS, , 2001. Treatment with benznidazole and its immunomodulating effects on experimentally Trypanosoma cruzi-infected rats. Parasitol Res 87: 539547.[Crossref]
  39. Daliry A, Caldas IS, de Figueiredo Diniz L, Torres RM, Talvani A, Bahia MT, de Carvalho AC, , 2014. Anti-adrenergic and muscarinic receptor autoantibodies in a canine model of Chagas disease and their modulation by benznidazole. Int J Cardiol 170: e66e67.[Crossref]
  40. Fernández MC, González Cappa SM, Solana ME, , 2010. Trypanosoma cruzi: immunological predictors of benznidazole efficacy during experimental infection. Exp Parasitol 124: 172180.[Crossref]
  41. Aliberti JC, Machado FS, Souto JT, Campanelli AP, Teixeira MM, Gazzinelli RT, Silva JS, , 1999. β-Chemokines enhance parasite uptake and promote nitric oxide-dependent microbiostatic activity in murine inflammatory macrophages infected with Trypanosoma cruzi . Infect Immun 67: 48194826.
  42. Teixeira MM, Gazzinelli RT, Silva JS, , 2002. Chemokines, inflammation and Trypanosoma cruzi infection. Trends Parasitol 18: 262265.[Crossref]
  43. Machado FS, Koyama NS, Carregaro V, Ferreira BR, Milanezi CM, Teixeira MM, Rossi MA, Silva JS, , 2005. CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi . J Infect Dis 191: 627636.[Crossref]
  44. Hardison JL, Wrightsman RA, Carpenter PM, Kuziel WA, Lane TE, Manning JE, , 2006. The CC chemokine receptor 5 is important in control of parasite replication and acute cardiac inflammation following infection with Trypanosoma cruzi . Infect Immun 74: 135143.[Crossref]
  45. Marino AP, da Silva A, dos Santos P, Pinto LM, Gazzinelli RT, Teixeira MM, Lannes-Vieira J, , 2004. Regulated on activation, normal T cell expressed and secreted (RANTES) antagonist (Met-RANTES) controls the early phase of Trypanosoma cruzi-elicited myocarditis. Circulation 110: 14431449.[Crossref]
  46. Medeiros GA, Silverio JC, Marino AP, Roffe E, Vieira V, Kroll-Palhares K, Carvalho CE, Silva AA, Teixeira MM, Lannes-Vieira J, , 2009. Treatment of chronically Trypanosoma cruzi-infected mice with a CCR-1/CCR5 antagonist (Met-RANTES) results in amelioration of cardiac tissue damage. Microbes Infect 11: 264273.[Crossref]
  47. Paiva CN, Figueiredo RT, Kroll-Palhares K, Silva AA, Silvério JC, Gibaldi D, Pyrrho A dos S, Benjamim CF, Lannes-Vieira J, Bozza MT, , 2009. CCL2/MCP-1 controls parasite burden, cell infiltration, and mononuclear activation during acute Trypanosoma cruzi infection. J Leukoc Biol 86: 12391246.[Crossref]
  48. Guedes-da-Silva FH, Shrestha D, Salles BC, Figueiredo VP, Lopes LR, Dias L, Barcelos LS, Moura S, de Andrade SP, Talvani A, , 2015. Trypanosoma cruzi antigens induce inflammatory angiogenesis in a mouse subcutaneous sponge model. Microvasc Res 97: 130136.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.15-0237
Loading
/content/journals/10.4269/ajtmh.15-0237
Loading

Data & Media loading...

  • Received : 25 Mar 2015
  • Accepted : 03 Jul 2015

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error